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Novel Anticoagulants for
Stroke Prevention in Atrial Fibrillation
Current Clinical Evidence and Future Developments
Stephan H. Schirmer, MD, PHD,* Magnus Baumhäkel, MD,* Hans-Ruprecht Neuberger, MD, PHD,*
Stefan H. Hohnloser, MD,† Isabelle C. van Gelder, MD, PHD,‡§ Gregory Y. H. Lip, MD,
Michael Böhm, MD*
Homburg/Saar and Frankfurt, Germany; Groningen and Utrecht, the Netherlands;
and Birmingham, England, United Kingdom
Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for ischemic stroke.
Antithrombotic therapy using aspirin or vitamin K antagonists (VKA) is currently prescribed for prevention for
ischemic stroke in patients with AF. A narrow therapeutic range and the need of regular monitoring of its antico-
agulatory effect impair effectiveness and safety of VKA, causing a need for alternative anticoagulant drugs. Re-
cently developed anticoagulants include direct thrombin antagonists such as dabigatran or factor Xa inhibitors
such as rivaroxaban, apixaban, betrixaban, and edoxaban. Currently, data from a phase III clinical trial are avail-
able for dabigatran only, which show the direct thrombin antagonist to be at least noninferior in efficacy to VKA
for the prevention of stroke and systemic embolism in patients with AF. This review focuses on current advances
in the development of directly acting oral anticoagulant drugs and their potential to replace the VKA class of
drugs in patients with AF. (J Am Coll Cardiol 2010;56:2067–76) © 2010 by the American College of Cardiol-
ogy Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.09.017f
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utrial fibrillation (AF) affects more than 1% of the general
opulation, and its prevalence rises up to 10% in people
lder than 80 years of age (1–2). It is estimated that nearly
6 million people will suffer from AF in the U.S. by 2050
3). AF is known to be a substantial independent risk factor
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010, accepted September 23, 2010.or ischemic stroke, irrespective of temporal pattern of AF,
hether paroxysmal, persistent, or permanent (4–7), and
mportantly, AF-related stroke confers a significantly in-
reased mortality and morbidity compared with non-AF
auses of stroke (8–10). Apart from its impact on health and
urvival, AF imposes an enormous economic burden. It is
stimated that AF causes yearly direct and indirect costs of
66 billion per year (11).
Currently, aspirin and vitamin K antagonists (VKA) are
he only approved antithrombotic therapies for stroke pre-
ention in patients with AF (12). VKA therapy is clearly
ecommended in patients with a CHADS2 (congestive
eart failure, hypertension, age 75 years, diabetes, and
revious stroke/transient ischemic attack) score of 2 or
igher. At a CHADS2 score of 1, VKA may be preferred
ver aspirin if the thromboembolic risk is judged higher
han that of bleeding complications, or if other stroke risk
actors (e.g., female sex, vascular disease, and so on) that are
ot included in the CHADS2 score are considered, which
as been expressed as the CHA2DS2-VASc (CHADS2–
ascular disease, age 65 to 74 years, sex category) score
13,14).
The use of VKA, however, necessitates regular anticoag-
lation monitoring. Interactions of warfarin with food and
ther drugs also hamper its use. Intensity of oral anticoag-
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come, with the necessity to
maintain a narrow therapeutic
range as measured by the inter-
national normalized ratio (INR)
of 2 to 3 (15). Even within the
setting of a randomized controlled
trial, patients are within the ther-
apeutic range for only two-thirds
of the time (16), and in daily
clinical practice, therapeutic
range is achieved to an even
lesser extent (17). Furthermore,
oral anticoagulation using warfa-
rin is associated with a significant
risk of major bleeding (approxi-
ately 2%/year). Importantly, more recent data suggest that
lso antiplatelet therapy confers a similar (BAFTA [Birming-
am Atrial Fibrillation Treatment of the Aged] study) (18) or
ven greater (ACTIVE-W [Atrial fibrillation Clopidogrel
rial with Irbesartan for prevention of Vascular Events]) (19)
isk of major bleeding, with aspirin or aspirin–
lopidogrel combination therapy, respectively. Because of
he difficulties of warfarin therapy and the large number
f patients in need of anticoagulation in AF, alternative
herapeutic strategies have long been sought after.
Commonly used anticoagulants such as unfractionated
nd low molecular weight heparin act by binding to anti-
hrombin and inhibiting both thrombin and activated factor
a. Direct inhibition of factor Xa and of thrombin are
articularly interesting approaches. The former might
ause more coagulation-specific effects, whereas the latter
ight have beneficial effects outside the coagulation
ascade, e.g., by interfering with the effects of thrombin
n PAR (protease activated receptor) receptors on plate-
ets, endothelial cells, or vascular smooth muscle cells
20) (Fig. 1).
Thus, novel anticoagulant drugs were developed with the
im of an orally available compound that did not require
onitoring of the anticoagulatory effect but could be ap-
lied at a fixed dose. A small number of anticoagulants have
eached phase III clinical studies for use in AF. Usually, the
afety and efficacy of novel anticoagulants are first tested in
atients undergoing elective hip or knee replacement sur-
ery. This approach is particularly suitable for anticoagulant
rug development because of study populations with a
elatively high rate of thrombotic events and the possibility
f monitoring bleeding events in a hospital environment.
mong the factor Xa inhibitors, apixaban, betrixaban,
doxaban, and rivaroxaban are the most advanced com-
ounds. A phase III clinical trial comparing apixaban to
spirin in patients unsuitable for VKA has recently been
topped. In the comparison to VKA, dabigatran currently is
he furthest developed oral direct thrombin inhibitor and
he only novel anticoagulant for which data from a phase III
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
AF  atrial fibrillation
b.i.d.  twice daily
CI  confidence interval
INR  international
normalized ratio
RR  relative risk
VKA  vitamin K
antagonists
VTE  venous
thromboembolismrial for stroke prevention in AF are available.linical Data on Direct Thrombin Inhibitors
echanisms of action. In contrast to factor Xa inhibitors,
irect thrombin inhibitors have more diverse effects on the
oagulation. They prevent fibrin formation, thrombin-
ediated activation of factors V, VIII, XI, and XIII, and
hrombin-induced platelet aggregation. The latter is in
ontrast to unfractionated heparin, which is known to
ctivate platelets (21,22). Similarly to factor Xa inhibitors,
issue factor–induced thrombin generation is attenuated by
hrombin inhibitors (23). Also in contrast to heparins, direct
hrombin inhibitors have the capacity to act on fibrin-bound
hrombin (24), causing a more efficient inhibition than
ndirect thrombin inhibitors acting further upstream in the
oagulation cascade (Fig. 1). In theory, this effect can also
ncrease the risk of bleeding.
Among direct thrombin inhibitors, monovalent com-
ounds can be distinguished from bivalent inhibitors. Biva-
ent direct thrombin inhibitors include hirudin and bivaliru-
in, both of which have to be applied intravenously. In
ontrast, argatroban, ximelagatran, and dabigatran are uni-
alent direct thrombin inhibitors, the latter 2 having been
eveloped for oral use.
imelagatran. Ximelagatran was first evaluated in ortho-
edic trials, where it showed superiority over warfarin (25).
ts efficacy in stroke prevention in patients with AF was
emonstrated in 2 large, phase III studies, the open-label
Figure 1 Coagulation Cascade
Both the intrinsic coagulation pathway (involving factors XII, XI, IX, and VIII) as
well as the extrinsic pathway (involving factor VII) end in the same common
pathway, the activation of factor X to factor Xa. Together with factor Va, factor
Xa forms the prothrombinase complex that activates prothrombin (factor II) to
thrombin (factor IIa). In contrast to indirect anticoagulants such as heparins,
which require antithrombin III to inhibit factor Xa or factor IIa, the novel, orally
available inhibitors directly inhibit for Xa or factor IIa. Thrombin not only acti-
vates fibrinogen into fibrin (factor Ia), but also activates factors V, VII, VIII, IX,
and XIII. Blocking thrombin thus efficiently inhibits coagulation. Figure illustra-
tion by Craig Skaggs.
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in Inhibitor in Atrial Fibrillation) trial (26) and the
ouble-blind SPORTIF V trial (27), which followed-up
,410 patients (70.2  8.6 years) for 17 months and 3,922
atients (71.6  9.1 years) for 20 months, respectively. In
PORTIF V, the annual risk for stroke or systemic embo-
ism (composite primary end point) was 1.6% with ximel-
gatran compared with 1.2% to 2.3% for warfarin (27). At
he same time, bleeding was less frequent with ximelagatran
han with warfarin (1.9% vs. 2.5%). Ximelagatran has also
een investigated in secondary prevention after acute myo-
ardial infarction, where it reduced a combined end point of
ortality, reinfarction, and stroke when compared with
lacebo (28). However, hepatotoxicity, as indicated by a
elevant (more than 3 times the upper limit of normal)
ncrease in alanine aminotransferase, was observed in several
tudies in up to 6.1% compared with 0.8% in patients
eceiving warfarin. As a consequence, ximelagatran was
ithdrawn from all markets and from further development
n February 2006.
abigatran. Dabigatran is a direct reversible thrombin
nhibitor. Its oral pro-drug, dabigatran etexilate, which is
onverted by serum esterases to dabigatran, has a bioavail-
bility of 6.5%, a half-life of 12 to 17 h and is renally
xcreted by approximately 80% (29). Although it does not
equire regular dose monitoring, anticoagulant status can be
ssessed by measuring thrombin clotting time or ecarin
lotting time, which might be valuable in case of bleeding
30). Although the activated partial thromboplastin time
ay not be suitable for the precise quantification of antico-
gulant effect at high plasma concentrations of dabigatran, it
ay be useful to indicate excessive anticoagulant effects in
mergency situations (30).
A large study program, called the (RE-VOLUTION
rogram) was initiated to investigate the effect of dabigatran
n different settings (prevention and treatment of venous
hromboembolism [VTE], prevention of stroke in AF, and
econdary prevention of acute coronary syndrome [ACS]).
hase III testing of dabigatran started with trials to prevent
TE after orthopedic surgery. In the RE-NOVATE
Dabigatran Etexilate Compared With Enoxaparin in Pre-
ention of VTE Following Total Hip Arthroplasty) study,
50 mg and 220 mg of dabigatran once daily were nonin-
erior to 40-mg enoxaparin daily for 33 days (end point:
omposite of VTE and death) without a significant increase
n bleeding in 3,494 patients age 64  11 years following
otal hip replacement (31). The recently presented RE-
OVATE II trial also showed extended thromboprophy-
axis after hip arthroplasty in 2,055 patients using 220-mg
abigatran for 28 to 35 days to be noninferior (same end
oint as RE-NOVATE) to 40-mg enoxaparin (32). Also,
fter total knee replacement, dabigatran proved to be non-
nferior (end point: composite of VTE and death) to
noxaparin in 2,076 patients age 68  9 years, followed-up
or 3 months after 6 to 10 days of treatment (RE-MODEL
Dabigatran Etexilate 150 or 220 mg o.d. vs. Enoxaparin p0 mg o.d. for Prevention of Thrombosis After Knee Surgery]
rial) (33). When compared with a higher dose scheme of
noxaparin (2  30 mg daily) in the RE-MOBILIZE
Dabigatran Etexilate vs Enoxaparin in Prevention of VTE
ost Total Knee Replacement) trial, dabigatran for 12 to 15
ays was inferior in the prevention of VTE in 1,896 patients
ge 66  10 years (34). In a pooled analysis of all 3 trials,
riedman et al. (35) found noninferiority and similar
leeding rates of dabigatran compared with enoxaparin. A
ecent Cochrane meta-analysis on total hip and knee re-
lacements concluded direct thrombin antagonist to be as
ffective as low molecular weight heparin or VKA in the
revention of VTE (36).
A trial investigating treatment of acute VTE in 2,539
atients age 55  15 years (the RE-COVER trial) recently
emonstrated noninferior efficacy (end point: recurrent
ymptomatic, objectively confirmed VTE and related death)
f a fixed dose of dabigatran (150 mg twice daily [b.i.d.]) to
arfarin with a similar major bleeding profile during 6
onths of therapy (37). Investigations analyzing the effects
f dabigatran on long-term prevention of recurrent and of
cute symptomatic VTE are currently recruiting patients
Twice-Daily Oral Direct Thrombin Inhibitor Dabigatran
texilate in the Long Term Prevention of Recurrent Symp-
omatic VTE: NCT00558259; Secondary Prevention of
enous Thrombo Embolism: NCT00329238; and Phase
II Study Testing Efficacy and Safety of Oral Dabigatran
texilate vs Warfarin for 6 m Treatment for Acute Symp-
omatic VTE: NCT00680186, respectively).
Following the noninferiority studies in the prevention of
TE after orthopedic surgery, the safety and effectiveness of
abigatran in stroke prevention in 502 patients with AF was
rst investigated in the PETRO (Prevention of Embolic
nd ThROmbotic events) phase II trial that suggested
eduction of thromboembolic events with dabigatran doses
f 150 or 300 mg twice daily (38). Subsequently, stroke
revention was tested in the large, phase III RE-LY
Randomized Evaluation of Long-term anticoagulation
herapY) trial that included 18,113 patients with AF
39,40). In RE-LY, patients were randomized to receive
ither a fixed dose of 110- or 150-mg dabigatran b.i.d. or
arfarin at an adjusted dose to reach an INR of 2.0 to 3.0
Table 1) (40). The primary outcome at a median follow-up
f 2 years, stroke or systemic embolism, occurred as often in
atients taking 110-mg dabigatran b.i.d. as in patients on
arfarin (1.5% vs. 1.7%, relative risk [RR]: 0.91, 95%
onfidence interval [CI]: 0.74 to 1.11, p  0.34), and less
ften (1.1%, RR: 0.66, 95% CI: 0.53 to 0.82, p  0.001) in
hose taking 150-mg dabigatran b.i.d. (Fig. 2). Importantly,
emorrhagic stroke occurred significantly less often in
atients on low-dose (0.12% per year, RR: 0.31, 95% CI:
.17 to 0.56; p  0.001) and on high-dose dabigatran
0.10% per year, RR: 0.26, 95% CI: 0.14 to 0.49; p 0.001)
ompared with patients taking warfarin (0.38% per year). A
omparable rate of major bleeding was observed in those
atients on high-dose dabigatran and in patients taking
Comparison of the Hitherto Conducted or Ongoing Phase III Trials in AFTable 1 Comparison of the Hitherto Conducted or Ongoing Phase III Trials in AF
Drug Study Name Patients Primary End Point Secondary End Points Follow-Up Results (Primary End Point) Comments
Dabigatran
110 mg/150 mg
b.i.d.
Warfarin
INR 2–3
RE-LY 18,113 patients
AF
1 risk factor
50% VKA naive
CHADS2 0–1: c. 32%
CHADS2 2: c. 35%
CHADS2 3: c. 33%
Composite: stroke/
systemic embolism
1. Myocardial infarction
2. Pulmonary embolism
3. Hospitalization
4. Total mortality
5. Cardiovascular mortality
Event-driven (n  450),
12 months
Low-dose dabigatran equally
effective, high dose
superior to warfarin
Open-label warfarin
Rivaroxaban
20 mg o.d.
Warfarin
INR 2–3
ROCKET-AF 14,000 patients
AF
moderate/high risk
CHADS2 2: 10%
CHADS2 3: 90%
Composite: stroke/
systemic embolism
1. Composite: TIA/
all-cause mortality/
vascular mortality/
myocardial infarction
Event-driven (n  405),
14 months
Study completed January
2010, data awaited
end 2010
Double-dummy design with
sham INR
Apixaban
5 mg b.i.d.
Warfarin
INR 2–3
ARISTOTLE 18,205 patients
AF
1 risk factor
Both VKA naive/non-naive
Composite: stroke/
systemic embolism
1. Composite: stroke/
systemic embolism/
all-cause mortality
2. Composite: stroke/
systemic embolism/
all-cause mortality/
major bleeding
3. Composite: stroke/
systemic embolism/
major bleeding/
myocardial infarction
Event-driven (n  448),
12 months
Patient recruitment
completed, study end
expected April 2011
Double-dummy design with sham
INR, stroke diagnosis by
neurologists
Apixaban
5 mg b.i.d.
Aspirin
81–32 mg o.d.
AVERROES 5,600 patients
AF
1 risk factor
Intolerant/unsuitable for VKA
Composite: stroke/
systemic embolism
1. Time from first dose of
study drug to first
occurrence of ischemic
stroke, hemorrhagic stroke,
systemic embolism,
myocardial infarction, or
vascular death
Event-driven, 36 months Apixaban superior to aspirin,
no increased risk of
bleeding
Prematurely stopped after
evidence of superiority of
study drug to aspirin
Edoxaban
30 mg/60 mg o.d.
Warfarin
ENGAGE-AF–
TIMI 48
20,500 patients (estimated)
AF
Moderate risk (CHADS2 2)
Composite: stroke/
systemic embolism
1. Composite: stroke/
systemic embolism/
all-cause mortality
2. Major bleeding
Time frame: 24 months Study completion expected
March 2012
AF atrial fibrillation; ARISTOTLE Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation; AVERROES A Phase III Study of Apixaban in Patients With Atrial Fibrillation; b.i.d. twice daily; CHADS2 (congestive heart failure, hypertension, age75 years,
diabetes, and previous stroke/transient ischemic attack); ENGAGE-AF  Global Study to Assess the Safety and Effectiveness of DU-176b vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation; INR  international normalized ratio; o.d.  daily;
RE-LY  Randomized Evaluation of Long-term anticoagulation therapY; ROCKET-AF  Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation;
VKA  vitamin K antagonist.
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as a lower bleeding rate in patients taking the lower dose
f dabigatran (RR: 0.80, 95% CI: 0.69 to 0.93, p  0.003).
otal bleeding was reduced with both 110- and 150-mg
abigatran (Fig. 3). In detail, intracranial bleeding was
educed from 0.7% with warfarin to 0.3% with high-dose
nd to 0.2% with low-dose dabigatran. Gastrointestinal
leeding, however, was increased from 1.0% per year with
arfarin to 1.1% with low-dose and to 1.5% with high-dose
abigatran. Importantly, there was a reduction in all-cause
ortality with 150-mg dabigatran compared with warfarin
RR: 0.88) that almost reached statistical significance (p 
.051) (Fig. 4) and a significant reduction in vascular
ortality (RR: 0.85, p  0.04). A recent RE-LY subanaly-
is showed that dabigatran is at least noninferior to warfarin
Figure 2 Cumulative Hazard Rates for the Primary End Point
(Stroke or Systemic Embolism) in the RE-LY Trial
The end point occurred in 1.69% per year in the warfarin group versus 1.53%
with 110-mg dabigatran taken twice daily (RR: 0.91, 95% CI: 0.74 to 1.11,
p  0.001 for noninferiority) and in 1.11% per year in the 150-mg dabigatran
group (RR: 0.66, 95% CI: 0.53 to 0.82, p  0.001 for superiority). Adapted,
with permission, from Connolly et al. (39). CI  confidence interval; RE-LY 
Randomized Evaluation of Long-term anticoagulation therapy; RR  relative
risk.
Figure 3 Total Bleeding in the RE-LY Trial
Total bleeding was significantly reduced with both 150-mg (16.4% per year, RR:
0.91, 95% CI: 0.86 to 0.97, p  0.002) and 110-mg (14.6% per year, RR:
0.78, 95% CI: 0.74 to 0.83, p  0.001) dabigatran compared with warfarin
(18.2% per year). Adapted, with permission, from Connolly et al. (39). Abbrevia-
tions as in Figure 2.cn all subgroups of AF patients at low, moderate, or high
isk of stroke (41). Analyzing the primary end point (stroke
r systemic embolism) of the RE-LY study in relation to
he time-in-therapeutic range of patients treated with
arfarin showed that beneficial effects of dabigatran over
arfarin were consistent irrespective of INR control. For
he end points cardiovascular events and total mortality,
abigatran was superior to warfarin at low time-in-
herapeutic range (42).
For unknown reasons, an increased rate of myocardial
nfarction was seen with dabigatran compared with warfarin
0.7% vs. 0.5%), which reached statistical significance for
igh-dose (p  0.048), but not low-dose (p  0.07)
abigatran. Upcoming subanalyses of RE-LY will deliver
nswers on the combination therapy of aspirin and dabig-
tran. A subanalysis on patients undergoing cardioversion,
resented at the meeting of the American College of
ardiology in March 2010, showed similarly low rates of
trokes of stroke in patients treated with dabigatran or
arfarin (43).
Recently, a phase II trial investigating the effect of a
-month treatment of dabigatran etexilate on top of aspirin
nd clopidogrel in 1,878 patients with ACS has been carried
ut (RE-DEEM [Dose Finding Study for Dabigatran
texilate in Patients With Acute Coronary Syndrome]
rial). Its results, which suggest that using additional anti-
latelet therapy with dabigatran in patients after percutane-
us coronary intervention is safe, were first presented at the
merican Heart Association Scientific Sessions 2009. This
s of relevance in a relatively large group of patients with AF
ndergoing percutaneous coronary intervention for stable
oronary artery disease or ACS (44).
Notably, no significant rise in liver enzymes was noted
uring the entire dabigatran study program. The pharma-
okinetic profile of dabigatran shows no interaction with
Figure 4 All-Cause Mortality in the RE-LY Trial
The 12% reduction (95% CI: 0.77 to 1.00) in all-cause mortality with 150-mg
(3.6%) dabigatran compared with warfarin (4.1%) almost reached statistical
significance (p  0.051). Adapted, with permission, from Connolly et al. (39).
Abbreviations as in Figure 2.ytochrome P450 enzymes. However, P-glycoprotein-
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Novel Anticoagulants in Atrial Fibrillation December 14/21, 2010:2067–76nhibitors such as amiodarone, verapamil or quinidine, all
sed in patients with AF, may lead to an increased plasma
oncentration of dabigatran and thus increase bleeding risk.
p to approximately 80% of dabigatran is eliminated via the
idneys, which is why the drug may accumulate when renal
unction is abnormal. However, a recent RE-LY subanalysis
resented at the annual meeting of the American College of
ardiology in March 2010 suggests that an interaction
etween renal function and treatment was not evident after
djustment for age (45). The benefit of dabigatran versus
arfarin in reducing major bleeding was shown to be
ignificantly attenuated with increasing age. However, the
eduction in hemorrhagic stroke with dabigatran remained
naffected by age (46).
Since March 2008, use of dabigatran for the prevention of
TE after elective hip and knee replacement has been
pproved by the accreditation authorities in Europe. An
conomic analysis comparing dabigatran to enoxaparin in
hrombosis prevention after hip replacement provided re-
uced costs with the oral thrombin inhibitor, which were
ainly due to high application costs of enoxaparin (47). In
atients with AF otherwise requiring VKA therapy, cost
nalyses will have to show how far the difference in drug
rice will be counterweighed by the omitted expenses of
egular anticoagulation monitoring. Total cost effectiveness
f dabigatran will be favorable over warfarin if costs of
isabling stroke could indeed be reduced because of superior
fficacy of the drug. A cost analysis for dabigatran in AF,
owever, has yet to be done. Another direct thrombin
ntagonist currently investigated, known as AZD0837, has
hown promising data in phase II studies in AF, where it
as noninferior to warfarin while showing a reduced bleed-
ng risk (48,49).
linical Data on Oral Factor Xa Inhibitors
echanisms of action. By inhibiting factor Xa, generation
f thrombin from prothrombin is attenuated. Besides, tissue
actor–induced thrombin generation is inhibited (50). As a
onsequence, prothrombin time increases with factor Xa
nhibition in a dose-dependent fashion. Parenterally appli-
able factor Xa inhibitors—fondaparinux, idraparinux—are
ndirect (i.e., they require antithrombin as a cofactor).
tamixaban is a novel intravenously applicable direct factor
a inhibitor with promising results for use after myocardial
nfarction (51). The focus of this review, however, lies on
he development of oral anti-factor Xa agents with the
otential to replace VKAs as anticoagulants in AF. A
rowing number of direct factor Xa inhibitors have entered
linical testing in recent years. The lack of induction of a
elease of platelet factor 4 and the lack of platelet activation
n the presence of heparin-induced thrombocytopenia anti-
odies have suggested factor Xa inhibitors such as rivaroxa-
an may be potential drugs for the management of patients
ith heparin-induced thrombocytopenia (52). Phase III
ata on factor Xa inhibitors is currently available for the vrevention of VTE only. The first phase III trial comparing
hese drugs to VKA for stroke prevention in AF
ROCKET-AF [Randomized, Double-Blind Study Com-
aring Once Daily Oral Rivaroxaban With Adjusted-Dose
ral Warfarin for the Prevention of Stroke in Subjects
ith Non-Valvular Atrial Fibrillation]) is still in progress.
ivaroxaban. Rivaroxaban has a bioavailability of 80%, a
lasma half-life of 7 to 11 h, and is metabolized in the liver
y two-thirds, whereas one-third undergoes unchanged
enal excretion (53). Phase III orthopedic trials have dem-
nstrated noninferior or even superior efficacy in VTE
revention of rivaroxaban compared with enoxaparin. For
xample, rivaroxaban led to RR reductions of 70% to 78% of
he primary end point (composite of deep vein thrombosis,
onfatal pulmonary embolism, or death) compared with
noxaparin in the RECORD1 (Rivaroxban [10 mg] Given
nce Daily in Patients Undergoing Total Hip Replacement
ompared to Enoxaparin) study, which compared both
rugs over a 5-week period in 4,541 patients (mean age 63
ears) after total hip replacement (54), and in the
ECORD2 study using enoxaparin for 2 weeks and rivar-
xaban for 5 weeks in 2,509 patients age 62 14 years (55).
fter total knee replacement, rivaroxaban was superior to
noxaparin (end point composite of any deep vein throm-
osis, nonfatal pulmonary embolism, or death) when com-
ared over a period of 14 days post-operatively in 2,531
atients (mean age 68 years) in the RECORD3 (56) and
,148 (age 65  10 years) patients in the RECORD4 (57)
tudy, the latter trial comparing rivaroxaban to 2  30-mg
noxaparin. Results of the EINSTEIN (Oral Direct Factor
a Inhibitor Rivaroxaban In Patients With Acute Symp-
omatic Deep-Vein Thrombosis Without Symptomatic
ulmonary Embolism: Einstein-DVT Evaluation) study,
hich included 3,449 patients treated for acute deep vein
hrombosis, were presented at the annual meeting of the
uropean Society of Cardiology in August 2010. The study
howed noninferiority of rivaroxaban compared with enox-
parin/warfarin with comparable safety profiles. Another
hase III investigation in the prevention of primary VTE
ith rivaroxaban (MAGELLAN [Venous Thromboem-
olic Event (VTE) Prophylaxis in Medically Ill Patients]
tudy) is currently being performed. Following approval for
se after orthopedic surgery in Europe, the U.S. Food and
rug Administration halted its favorable review because of
ome safety concerns in the EINSTEIN-extension study,
here a nonsignificant increase in major bleeding and in
iver enzymes had been noted with rivaroxaban (58).
The effect of rivaroxaban in AF is currently investigated
n the phase III ROCKET AF study, in which more than
4,000 patients have been randomized to receive 20 mg of
ivaroxaban daily or warfarin, dose-adjusted to an INR of
.0 to 3.0 (Table 1) (59). Its results are expected to become
vailable by late 2010. An important feature of the
OCKET AF trial is the fact that is was performed in a
ouble-blind manner, with computer-generated sham INR
alues provided for patients on rivaroxaban. In contrast to
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lthough the advantages of double-blind trials in examining
nticoagulants have recently been challenged (60).
In the recently completed phase II ATLAS ACS–TIMI 46
Rivaroxaban in Combination With Aspirin Alone or With
spirin and a Thienopyridine in Patients With Acute
oronary Syndromes) trial, increasing doses of rivaroxaban
s secondary prevention of major cardiovascular events in
,491 patients with ACS resulted in dose-dependent in-
reases of bleeding but reduction of the secondary end point
f death, myocardial infarction and stroke (61), warranting
he larger phase III trial ATLAS–TIMI 51, which is
urrently recruiting patients.
pixaban. In a phase III investigation to prevent throm-
oembolism after total knee replacement (ADVANCE-1
Study of an Investigational Drug for the Prevention of
hrombosis-Related Events Following Knee Replacement
urgery]), the use of 2.5-mg apixaban twice daily failed to
eet the noninferiority criteria (primary end point: com-
osite of deep vein thrombosis, nonfatal pulmonary embo-
ism, and death) when compared with 2  30-mg enoxapa-
in daily for 10 to 14 days in 3,195 patients (mean age 66
ears), albeit resulting in a lower risk of bleeding (62). In
nother phase III trial to prevent VTE after knee replace-
ent in 3,057 patients with a mean age of 66 years, the
DVANCE-2 trial, apixaban was superior to 40-mg enox-
parin daily for 10 to 14 days without an increase in
leeding (63). Other phase III investigations of apixaban for
he primary prevention (ADOPT [Study of Apixaban for
he Prevention of Thrombosis-Related Events in Patients
ith Acute Medical Illness]: NCT00457002) or treatment
f deep venous thrombosis and pulmonary embolism (Effi-
acy and Safety Study of Apixaban for the Treatment of
eep Vein Thrombosis or Pulmonary Embolism:
CT00643201) are currently recruiting patients.
In a phase II study (APPRAISE [Apixaban for Preven-
ion of Acute Ischemic and Safety Events] study) in 1,715
atients with ACS, apixaban led to a dose-dependent
ncrease in bleeding and a trend towards a reduction of
ecurrent ischemic events (64). A phase III trial is currently
ecruiting participants (Phase III Acute Coronary Syn-
rome [APPRAISE-2]: NCT00831441).
A large phase III trial in patients with AF, the ARISTOTLE
Apixaban for the Prevention of Stroke in Subjects With Atrial
ibrillation) trial comparing apixaban to warfarin, is cur-
ently being conducted (Table 1). Enrolment of 18,206
atients has been completed, and study results are expected
n April 2011 (65). The AVERROES study (A Phase III
tudy of Apixaban in Patients With Atrial Fibrillation:
CT00496769), which compared apixaban to aspirin (end
oint: composite of stroke or systemic embolism, see also
able 1) in patients with AF unsuitable for VKA therapy
66), was halted prematurely because of a superior efficacy of
he study drug in reducing thromboembolic events (67).
he results were presented at the annual meeting of the
uropean Society of Cardiology in August 2010. A total of t,809 patients treated with apixaban showed a 56% reduc-
ion in stroke or systemic embolism without excessive risk of
ncreased bleeding compared with aspirin.
etrixaban. Another factor Xa antagonist, betrixaban, has
o far only been tested in phase II studies, where it has
emonstrated safety in the EXPERT (A randomized eval-
ation of betrixaban, an oral factor Xa inhibitor, for pre-
ention of thromboembolic events after total knee replace-
ent) trial in 215 patients after total knee replacement (68).
he results of the phase II trial of betrixaban in AF have
een presented at the annual meeting of the American
ollege of Cardiology in March 2010, where betrixaban was
lso shown to be safe, with a dose-dependent risk of
leeding comparable to that of warfarin (EXPLORE-Xa
Phase 2 Study of the Safety, Tolerability and Pilot Efficacy
f Oral Factor Xa Inhibitor Betrixaban Compared to
arfarin] trial) (45). Importantly, betrixaban is the only
ew anticoagulant that is excreted almost unchanged
hrough bile with minimal renal excretion (5%), making it
articularly suitable for use in patients with renal failure.
doxaban. Of the latest of the new anticoagulants, edoxa-
an, 1 phase I trial has been published so far (69). A phase
II study comparing its effects to warfarin in patients with
F is currently being performed (ENGAGE-AF–TIMI 48
rial [Global Study to Assess the Safety and Effectiveness of
U-176b vs. Standard Practice of Dosing With Warfarin in
atients With Atrial Fibrillation]: NCT00781391) (Table 1).
lso, a phase III trial comparing edoxaban to warfarin for
he treatment of VTE, the Edoxaban Hokusai-VTE study
Comparative Investigation of Low Molecular Weight
LMW) Heparin/Edoxaban Tosylate (DU176b) Versus
LMW) Heparin/Warfarin in the Treatment of Symptom-
tic Deep-Vein Blood Clots and/or Lung Blood Clots:
CT00986154), is actively recruiting patients.
ther compounds. Other factor Xa inhibitors in clinical
evelopment include YM150 (70), which is being examined
n a phase II trial in AF (A Study Evaluating Safety and
olerability of YM150 Compared to Warfarin in Subjects
ith Atrial Fibrillation: NCT00938730) and LY-517717,
hich has hitherto only been investigated in knee arthro-
lasty (71).
otential Limitations
ome of the advantages of the newly developed drugs might
ranslate into disadvantages in clinical practice. The nonre-
uirement for regular anticoagulation monitoring also pro-
ides a lack of laboratory monitoring in case of bleeding or
hrombosis. Thus, patient adherence cannot be tested as it
an with VKA. Some of the novel agents require twice daily
osing, again potentially lowering effectiveness of the
rug in patients with low compliance. Similarly, rather
ast onset and offset of the novel compounds compared
ith VKA may translate into a disadvantage in these
atients. Antidotes have not been developed yet for drugs
hat have almost reached bedside of patients with AF,
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herapy and hemodialysis in dabigatran overdose, have
een proposed (30).
hrombin and Vascular Pathophysiology:
eyond Anticoagulation
part from its role as the effector molecule of the coagula-
ion cascade, thrombin exerts other, often detrimental
ffects in cardiovascular pathophysiology. Outside of blood
lotting, thrombin acts via protease-activated receptors
PAR) and thrombomodulin, both of which become up-
egulated upon vascular injury as in atherosclerosis. Endo-
helial dysfunction is the primary event in atherosclerosis
72). Thrombin has a negative effect on endothelial func-
ion, inhibiting nitric oxide (NO) production and increasing
ndothelin expression by stimulating endothelin converting
nzyme via a Rho/ROCK and ERK pathways, respectively
73). A stimulatory effect of thrombin on arginase contrib-
tes to reduced NO bioavailability (74). Inhibition of
ndothelial nitric oxide synthase and impairment of endo-
helial function by thrombin suggest that thrombin inhibi-
ors potentially exert antiatherosclerotic effects (73).
The thrombin receptor PAR1 is essential for leukocyte
ecruitment and inflammation (75). Inflammatory cell re-
ruitment into atherosclerotic plaques might therefore be
nhibited by thrombin antagonists. AF is commonly found
n patients suffering from atherosclerosis, and inflammatory
ells contribute to atherosclerotic plaque instability (76,77).
otentially, patients with atherosclerotic disease and AF
enefit from a thrombin inhibitor–caused reduction of
nflammation in the atherosclerotic plaque. De novo athero-
enesis, however, might not be ameliorated by thrombin
ntagonism, as suggested by reduced transendothelial
onocyte migration in hypercoagulable mice (78). Recent
ata from pathological studies suggest an up-regulation of
hrombin by oxidative stress in endothelial cells, also impli-
ating a potential beneficial role of thrombin inhibition for
ascular biology (79).
By binding to PARs, thrombin causes vascular smooth
uscle cells to proliferate, thereby contributing to a growth
et stabilization of atherosclerotic plaques. Thrombin causes
ifferentiation of circulating mononuclear cells towards
mooth muscle cells by binding to PAR1 (80). A pro-
brotic effect of thrombin can be inhibited by dabigatran in
itro (81). Inhibiting thrombin by PAR antagonism inhib-
ted intimal hyperplasia (82). Interaction of thrombin with
hrombomodulin, on the other hand, will have the opposite
ffect, inhibiting vascular smooth muscle cell proliferation
83). The exact mechanisms of interference with thrombin
unction and their clinical significance will have to be
ubject to future investigations.
onclusions
here are a number of novel oral anticoagulants with
romising data for the prevention of stroke in AF. Several ofhem have proven to be at least noninferior to warfarin or
eparin in the prevention or treatment of AF-unrelated
hromboembolism. In AF, dabigatran was the first to
rovide data from a phase III trial, making it an alternative
o VKA. Although the novel anticoagulants are all very
ttractive in theory, data from large clinical trials are of
ritical importance as was strikingly demonstrated in the
ase of ximelagatran. Further studies will show whether
ther drugs such as the factor Xa inhibitors can raise similar
opes to replace the VKAs for stroke prevention in patients
ith AF. Conclusions on differences in effectiveness and safety
etween different new compounds will, however, be limited as
ong as head-to-head comparisons have not been carried out
for a comparison of the study designs, see Table 1). Safety
rofiles will play a decisive role in the race for the most
uccessful anticoagulant, when efficacy data of most currently
eveloped compounds show superiority to VKA. Future clin-
cal analyses will show whether direct factor Xa or thrombin
nhibitors have additional beneficial cardiovascular effects as
uggested by pre-clinical data.
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